Natalie A. Sims

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7861550/publications.pdf

Version: 2024-02-01

182 papers	14,210 citations	20036 63 h-index	24511 114 g-index

191 all docs	191 docs citations	191 times ranked	16638 citing authors

#	Article	IF	Citations
1	Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. Leukemia, 2022, 36, 333-347.	3.3	10
2	Measuring Bone Volume at Multiple Densities by Micro-computed Tomography. Bio-protocol, 2021, 11, e3873.	0.2	14
3	Bone loss markers in the earliest Pacific Islanders. Scientific Reports, 2021, 11, 3981.	1.6	5
4	Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R. Endocrine Reviews, 2021, 42, 383-406.	8.9	41
5	Rothmund-Thomson Syndrome-Like RECQL4 Truncating Mutations Cause a Haploinsufficient Low-Bone-Mass Phenotype in Mice. Molecular and Cellular Biology, 2021, 41, .	1.1	5
6	Bone Geometry Is Altered by Follistatinâ€Induced Muscle Growth in Young Adult Male Mice. JBMR Plus, 2021, 5, e10477.	1.3	6
7	Cortical bone development, maintenance and porosity: genetic alterations in humans and mice influencing chondrocytes, osteoclasts, osteoblasts and osteocytes. Cellular and Molecular Life Sciences, 2021, 78, 5755-5773.	2.4	32
8	Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells Through Multiple Mechanisms. Annual Review of Physiology, 2020, 82, 507-529.	5.6	154
9	The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathology. Experimental and Molecular Medicine, 2020, 52, 1185-1197.	3.2	45
10	Asymmetric midshaft femur remodeling in an adult male with left sided hip joint ankylosis, Metal Period Nagsabaran, Philippines. International Journal of Paleopathology, 2020, 31, 14-22.	0.8	6
11	Editorial Peer Reviewers as Shepherds, Rather Than Gatekeepers. Journal of Bone and Mineral Research, 2020, 36, 1220-1224.	3.1	4
12	Dmp1Cre-directed knockdown of parathyroid hormoneâ€"related protein (PTHrP) in murine decidua is associated with a life-long increase in bone mass, width, and strength in male progeny. Journal of Bone and Mineral Research, 2020, 36, 1999-2016.	3.1	4
13	Cortical bone maturation in mice requires SOCS3 suppression of gp130/STAT3 signalling in osteocytes. ELife, 2020, 9, .	2.8	21
14	Testing Bone Formation Induction by Calvarial Injection Assay in vivo. Bio-protocol, 2020, 10, e3560.	0.2	5
15	STAT3 Hyperactivation Due to SOCS3 Deletion in Murine Osteocytes Accentuates Responses to Exercise- and Load-Induced Bone Formation. Journal of Bone and Mineral Research, 2020, 37, 547-558.	3.1	8
16	Cellular Processes by Which Osteoblasts and Osteocytes Control Bone Mineral Deposition and Maturation Revealed by Stage-Specific EphrinB2 Knockdown. Current Osteoporosis Reports, 2019, 17, 270-280.	1.5	21
17	Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone. Nature Communications, 2019, 10, 3436.	5.8	48
18	Disrupted type II collagenolysis impairs angiogenesis, delays endochondral ossification and initiates aberrant ossification in mouse limbs. Matrix Biology, 2019, 83, 77-96.	1.5	12

#	Article	IF	Citations
19	Brief exposure to full length parathyroid hormone-related protein (PTHrP) causes persistent generation of cyclic AMP through an endocytosis-dependent mechanism. Biochemical Pharmacology, 2019, 169, 113627.	2.0	9
20	Osteopontin is An Important Regulative Component of the Fetal Bone Marrow Hematopoietic Stem Cell Niche. Cells, 2019, 8, 985.	1.8	23
21	Effect of rapamycin on bone mass and strength in the Î±2(I)â€G610C mouse model of osteogenesis imperfecta. Journal of Cellular and Molecular Medicine, 2019, 23, 1735-1745.	1.6	22
22	Deleting Suppressor of Cytokine Signaling-3 in chondrocytes reduces bone growth by disrupting mitogen-activated protein kinase signaling. Osteoarthritis and Cartilage, 2019, 27, 1557-1563.	0.6	14
23	Dynll1 is essential for development and promotes endochondral bone formation by regulating intraflagellar dynein function in primary cilia. Human Molecular Genetics, 2019, 28, 2573-2588.	1.4	8
24	IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis. Journal of Biological Chemistry, 2019, 294, 7850-7863.	1.6	54
25	Isolation, Purification, Generation, and Culture of Osteocytes. Methods in Molecular Biology, 2019, 1914, 39-51.	0.4	3
26	Overcoming natural Wnt inhibition to optimize therapy. Nature Reviews Rheumatology, 2019, 15, 67-68.	3.5	5
27	IL-6 trans -signalling mediates trabecular, but not cortical, bone loss after ovariectomy. Bone, 2018, 112, 120-127.	1.4	32
28	Absence of Calcitriol Causes Increased Lactational Bone Loss and Lower Milk Calcium but Does Not Impair Post-lactation Bone Recovery in Cyp27b1 Null Mice. Journal of Bone and Mineral Research, 2018, 33, 16-26.	3.1	26
29	Biomechanical testing of the calcified metacarpal articular surface and its association with subchondral bone microstructure in Thoroughbred racehorses. Equine Veterinary Journal, 2018, 50, 255-260.	0.9	6
30	Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. Journal of Bone and Mineral Research, 2018, 33, 137-153.	3.1	54
31	Macrophages Driving Heterotopic Ossification: Convergence of Genetically-Driven and Trauma-Driven Mechanisms. Journal of Bone and Mineral Research, 2018, 33, 365-366.	3.1	17
32	Osteoblasts Are Rapidly Ablated by Virus-Induced Systemic Inflammation following Lymphocytic Choriomeningitis Virus or Pneumonia Virus of Mice Infection in Mice. Journal of Immunology, 2018, 200, 632-642.	0.4	7
33	Adolescent Inhalant Abuse Results in Adrenal Dysfunction and a Hypermetabolic Phenotype with Persistent Growth Impairments. Neuroendocrinology, 2018, 107, 340-354.	1.2	6
34	Integrating Endocrine and Paracrine Influences on Bone; Lessons From Parathyroid Hormone and Parathyroid Hormone-Related Protein. , 2018, , 283-299.		0
35	Retinoic Acid Receptor Î³ Activity in Mesenchymal Stem Cells Regulates Endochondral Bone, Angiogenesis, and B Lymphopoiesis. Journal of Bone and Mineral Research, 2018, 33, 2202-2213.	3.1	20
36	Parathyroid Hormone-Related Protein Negatively Regulates Tumor Cell Dormancy Genes in a PTHR1/Cyclic AMP-Independent Manner. Frontiers in Endocrinology, 2018, 9, 241.	1.5	25

#	Article	IF	Citations
37	Differing Effects of Parathyroid Hormone, Alendronate, and Odanacatib on Bone Formation and on the Mineralization Process in Intracortical and Endocortical Bone of Ovariectomized Rabbits. Calcified Tissue International, 2018, 103, 625-637.	1.5	13
38	Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease. Journal of Clinical Investigation, 2018, 128, 2406-2418.	3.9	51
39	High dose dietary vitamin D 3 increases bone mass and strength in mice. Bone Reports, 2017, 6, 44-50.	0.2	38
40	Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6. Nature Communications, 2017, 8, 806.	5.8	32
41	Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI Insight, 2017, 2, .	2.3	87
42	Coupling: The Influences of Immune and Bone Cells. , 2016, , 169-185.		8
43	Prepubertal Di-n-Butyl Phthalate Exposure Alters Sertoli and Leydig Cell Function and Lowers Bone Density in Adult Male Mice. Endocrinology, 2016, 157, 2595-2603.	1.4	21
44	Does anti-sclerostin therapy promote inflammation in rheumatoid arthritis?. Nature Reviews Endocrinology, 2016, 12, 314-316.	4.3	1
45	Response to â€œLetter to the Editor: On osteocyte density in the human bodyâ€• Bone, 2016, 88, 73.	1.4	0
46	VPS35: Two Ways to Recycle the Parathyroid Hormone Receptor (PTH1R) in Osteoblasts. EBioMedicine, 2016, 9, 3-4.	2.7	1
47	Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation. Bone, 2016, 93, 146-154.	1.4	25
48	Senescent Osteocytes: Do They Cause Damage and Can They Be Targeted to Preserve the Skeleton?. Journal of Bone and Mineral Research, 2016, 31, 1917-1919.	3.1	11
49	Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption. International Journal of Biochemistry and Cell Biology, 2016, 79, 14-23.	1.2	96
50	Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass. Journal of Biological Chemistry, 2016, 291, 21703-21716.	1.6	39
51	Chondrocytic EphrinB2 promotes cartilage destruction by osteoclasts in endochondral ossification. Development (Cambridge), 2016, 143, 648-57.	1.2	25
52	Loss of GsÎ± in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. Journal of Biological Chemistry, 2016, 291, 1631-1642.	1.6	36
53	EphrinB2 Signalling in Osteoblast Differentiation, Bone Formation and Endochondral Ossification. Current Molecular Biology Reports, 2015, 1, 148-156.	0.8	5
54	Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?. Arthritis Research and Therapy, 2015, 17, 328.	1.6	10

#	Article	IF	Citations
55	Neurological heterotopic ossification following spinal cord injury is triggered by macrophageâ€mediated inflammation in muscle. Journal of Pathology, 2015, 236, 229-240.	2.1	131
56	Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?. Frontiers in Endocrinology, 2015, 6, 41.	1.5	140
57	RANKL/OPG; Critical role in bone physiology. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 131-139.	2.6	158
58	Parthenolide inhibits pro-inflammatory cytokine production and exhibits protective effects on progression of collagen-induced arthritis in a rat model. Scandinavian Journal of Rheumatology, 2015, 44, 182-191.	0.6	28
59	Cardiotrophin-like cytokine factor 1 (CLCF1) and neuropoietin (NP) signalling and their roles in development, adulthood, cancer and degenerative disorders. Cytokine and Growth Factor Reviews, 2015, 26, 517-522.	3.2	33
60	The DNA Helicase Recql4 Is Required for Normal Osteoblast Expansion and Osteosarcoma Formation. PLoS Genetics, 2015, 11, e1005160.	1.5	34
61	Ubiquitous expression of the Pik3ca ^{H1047R} mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. FASEB Journal, 2015, 29, 1426-1434.	0.2	24
62	RARÎ³ is a negative regulator of osteoclastogenesis. Journal of Steroid Biochemistry and Molecular Biology, 2015, 150, 46-53.	1.2	25
63	Quantifying the osteocyte network in the human skeleton. Bone, 2015, 75, 144-150.	1.4	226
64	Bindarit, an Inhibitor of Monocyte Chemotactic Protein Synthesis, Protects against Bone Loss Induced by Chikungunya Virus Infection. Journal of Virology, 2015, 89, 581-593.	1.5	98
65	Calcitonin Physiology, Saved by a Lysophospholipid. Journal of Bone and Mineral Research, 2015, 30, 212-215.	3.1	19
66	Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone. Bone, 2015, 81, 343-351.	1.4	47
67	Isolation and gene expression of haematopoietic-cell-free preparations of highly purified murine osteocytes. Bone, 2015, 72, 34-42.	1.4	42
68	Arthritogenic alphaviruses: new insights into arthritis and bone pathology. Trends in Microbiology, 2015, 23, 35-43.	3.5	58
69	gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation. Journal of Endocrinology, 2014, 223, 181-190.	1.2	26
70	Osteocyte cell death in subchondral bone following joint injury correlates with the severity of aggrecan loss in overlying cartilage. Osteoarthritis and Cartilage, 2014, 22, S341-S342.	0.6	0
71	Myokines (muscle-derived cytokines and chemokines) including ciliary neurotrophic factor (CNTF) inhibit osteoblast differentiation. Bone, 2014, 64, 47-56.	1.4	53
72	Cellâ€“Cell Signaling: Broadening Our View of the Basic Multicellular Unit. Calcified Tissue International, 2014, 94, 2-3.	1.5	14

#	Article	IF	Citations
73	Talking among Ourselves: Paracrine Control of Bone Formation within the Osteoblast Lineage. Calcified Tissue International, 2014, 94, 35-45.	1.5	28
74	Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib. Current Osteoporosis Reports, 2014, 12, 98-106.	1.5	53
75	Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKEy Reports, 2014, 3, 481.	2.7	536
76	Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6040-6045.	3.3	107
77	Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine, 2014, 68, 101-109.	1.4	38
78	Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. BoneKEy Reports, 2014, 3, 527.	2.7	58
79	The Primary Function of gp130 Signaling in Osteoblasts Is To Maintain Bone Formation and Strength, Rather Than Promote Osteoclast Formation. Journal of Bone and Mineral Research, 2014, 29, 1492-1505.	3.1	90
80	EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. FASEB Journal, 2014, 28, 4482-4496.	0.2	70
81	Decline in calcitonin receptor expression in osteocytes with age. Journal of Endocrinology, 2014, 221, 181-191.	1.2	20
82	Regulation of cortical and trabecular bone mass by communication between osteoblasts, osteocytes and osteoclasts. Archives of Biochemistry and Biophysics, 2014, 561, 22-28.	1.4	104
83	EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 2013, 28, 926-935.	3.1	42
84	Basic Principles of Bone Cell Biology. , 2013, , 5-26.		3
85	Lactating Ctcgrp Nulls Lose Twice the Normal Bone Mineral Content due to Fewer Osteoblasts and More Osteoclasts, Whereas Bone Mass Is Fully Restored After Weaning in Association With Up-Regulation of Wnt Signaling and Other Novel Genes. Endocrinology, 2013, 154, 1400-1413.	1.4	29
86	Integrating Endocrine and Paracrine Influences on Bone. , 2013, , 53-67.		1
87	Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 67-76.	1.8	24
88	Delayed development of specific thyroid hormone-regulated events in transthyretin null mice. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E23-E31.	1.8	28
89	New insights into osteocyte and osteoblast biology: support of osteoclast formation, PTH action and the role of Wnt16 (ASBMR 2013). IBMS BoneKEy, 2013, 10, .	0.1	1
90	EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. Journal of Bone and Mineral Research, 2013, 28, 912-925.	3.1	93

#	Article	IF	Citations
91	Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair. Bone, 2012, 50, 704-712.	1.4	25
92	Elevated Hypothalamic TCPTP in Obesity Contributes to Cellular Leptin Resistance. Cell Metabolism, 2012, 15, 925-926.	7.2	1
93	Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia, 2012, 26, 1594-1601.	3.3	136
94	Leukemia inhibitory factor: A paracrine mediator of bone metabolism. Growth Factors, 2012, 30, 76-87.	0.5	48
95	Strain-Dependent Differences in Bone Development, Myeloid Hyperplasia, Morbidity and Mortality in Ptpn2-Deficient Mice. PLoS ONE, 2012, 7, e36703.	1.1	33
96	Contrasting roles of leukemia inhibitory factor in murine bone development and remodeling involve region-specific changes in vascularization. Journal of Bone and Mineral Research, 2012, 27, 586-595.	3.1	65
97	Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. Journal of Bone and Mineral Research, 2012, 27, 902-912.	3.1	49
98	Intercellular Cross-Talk Among Bone Cells: New Factors and Pathways. Current Osteoporosis Reports, 2012, 10, 109-117.	1.5	107
99	Regulation of Sclerostin Expression by Paracrine and Endocrine Factors. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 98-107.	1.3	14
100	Interactions Among Osteoblasts, Osteoclasts, and Other Cells in Bone. , 2011, , 227-267.		3
101	Elevated Hypothalamic TCPTP in Obesity Contributes to Cellular Leptin Resistance. Cell Metabolism, 2011, 14, 684-699.	7.2	162
102	EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone, 2011, 48, 533-542.	1.4	79
103	Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated Non-Target Effects on Bone in Mice. PLoS ONE, 2011, 6, e19665.	1.1	26
104	Dissociation of Bone Resorption and Bone Formation in Adult Mice with a Non-Functional V-ATPase in Osteoclasts Leads to Increased Bone Strength. PLoS ONE, 2011, 6, e27482.	1.1	36
105	Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood, 2011, 117, 5631-5642.	0.6	123
106	255 OSTEOARTHRITIC ARTICULAR CARTILAGE EXPRESSES THE PTH RECEPTOR; PTH EFFECTS CARTILAGE METABOLISM. Osteoarthritis and Cartilage, 2011, 19, S122-S123.	0.6	2
107	Skeletal recovery after weaning does not require PTHrP. Journal of Bone and Mineral Research, 2011, 26, 1242-1251.	3.1	55
108	Zinc Finger Protein 467 Is a Novel Regulator of Osteoblast and Adipocyte Commitment. Journal of Biological Chemistry, 2011, 286, 4186-4198.	1.6	71

#	Article	IF	Citations
109	GsÎ± enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. Journal of Clinical Investigation, 2011, 121, 3492-3504.	3.9	91
110	EPHs and ephrins: Many pathways to regulate osteoblasts and osteoclasts. IBMS BoneKEy, 2010, 7, 304-313.	0.1	11
111	Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood, 2010, 116, 4815-4828.	0.6	695
112	Ciliary Neurotrophic Factor Inhibits Bone Formation and Plays a Sex-Specific Role in Bone Growth and Remodeling. Calcified Tissue International, 2010, 86, 261-270.	1.5	62
113	Building bone with a SOST-PTH partnership. Journal of Bone and Mineral Research, 2010, 25, 175-177.	3.1	18
114	The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 2010, 25, 1759-1770.	3.1	80
115	Theoretical investigation of the role of the RANKâ€“RANKLâ€“OPG system in bone remodeling. Journal of Theoretical Biology, 2010, 262, 306-316.	0.8	102
116	Adverse effects of valproate on bone: Defining a model to investigate the pathophysiology. Epilepsia, 2010, 51, 984-993.	2.6	43
117	Germline deletion of AMPâ€activated protein kinase Î² subunits reduces bone mass without altering osteoclast differentiation or function. FASEB Journal, 2010, 24, 275-285.	0.2	52
118	Lack of Sustained Response to Teriparatide in a Patient with Adult Hypophosphatasia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1007-1012.	1.8	65
119	Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone, 2010, 46, 1486-1497.	1.4	102
120	Severe developmental bone phenotype in ClC-7 deficient mice. Developmental Biology, 2010, 344, 1001-1010.	0.9	33
121	Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. Journal of Clinical Investigation, 2010, 120, 582-592.	3.9	245
122	Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Regulates Hematopoiesis and Bone Formation In Vivo. PLoS ONE, 2010, 5, e13086.	1.1	47
123	How Cells Communicate in the Bone Remodelling Process. Journal of Korean Endocrine Society, 2010, 25, 1.	0.1	2
124	GP130 cytokines and bone remodelling in health and disease. BMB Reports, 2010, 43, 513-523.	1.1	105
125	Molecular Mechanisms in Coupling of Bone Formation to Resorption. Critical Reviews in Eukaryotic Gene Expression, 2009, 19, 73-88.	0.4	142
126	The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16511-16516.	3.3	273

#	Article	IF	Citations
127	Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma. Clinical Cancer Research, 2009, 15, 1998-2009.	3.2	32
128	New insights into therapeutic drug interventions for catabolic bone diseases using an in-silico modeling approach. Bone, 2009, 44, S135-S136.	1.4	0
129	What is the true nature of the osteoblastic hematopoietic stem cell niche?. Trends in Endocrinology and Metabolism, 2009, 20, 303-309.	3.1	89
130	gp130 signaling in bone cell biology: Multiple roles revealed by analysis of genetically altered mice. Molecular and Cellular Endocrinology, 2009, 310, 30-39.	1.6	41
131	The Chemokine Cxcl1 Is a Novel Target Gene of Parathyroid Hormone (PTH)/PTH-Related Protein in Committed Osteoblasts. Endocrinology, 2009, 150, 2244-2253.	1.4	54
132	Communication Between EphrinB2 and EphB4 Within the Osteoblast Lineage. Advances in Experimental Medicine and Biology, 2009, 658, 51-60.	0.8	75
133	Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. Journal of Clinical Investigation, 2009, 119, 837-851.	3.9	244
134	Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporosis International, 2008, 19, 1125-1138.	1.3	39
135	EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts. Journal of Bone and Mineral Research, 2008, 23, 1170-1181.	3.1	191
136	Cardiotrophin-1 Is an Osteoclast-Derived Stimulus of Bone Formation Required for Normal Bone Remodeling. Journal of Bone and Mineral Research, 2008, 23, 2025-2032.	3.1	163
137	Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Seminars in Cell and Developmental Biology, 2008, 19, 444-451.	2.3	383
138	Intermittent Fugu parathyroid hormone 1 (1â€“34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. Bone, 2008, 42, 1164-1174.	1.4	10
139	Model structure and control of bone remodeling: A theoretical study. Bone, 2008, 43, 249-263.	1.4	237
140	Osteoclast Inhibitory Lectin, an Immune Cell Product That Is Required for Normal Bone Physiology in Vivo. Journal of Biological Chemistry, 2008, 283, 30850-30860.	1.6	28
141	IL-23 Inhibits Osteoclastogenesis Indirectly through Lymphocytes and Is Required for the Maintenance of Bone Mass in Mice. Journal of Immunology, 2008, 181, 5720-5729.	0.4	85
142	Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?. Blood, 2008, 111, 5411-5412.	0.6	18
143	Modulating chondrocyte hypertrophy in growth plate and osteoarthritic cartilage. Journal of Musculoskeletal Neuronal Interactions, 2008, 8, 308-10.	0.1	16
144	A Novel Mutation in the Nfkb2 Gene Generates an NF-Î²B2 â€œSuper Repressorâ€• Journal of Immunology, 2007, 179, 7514-7522.	0.4	77

#	Article	IF	Citations
145	Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density inPyk2â^'/â^'mice. Journal of Cell Biology, 2007, 178, 1053-1064.	2.3	208
146	Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Bone, 2007, 40, 305-315.	1.4	34
147	Rb Regulates Interactions between Hematopoietic Stem Cells and Their BoneÂMarrow Microenvironment. Cell, 2007, 129, 1081-1095.	13.5	380
148	Mechanisms Involved in Skeletal Anabolic Therapies. Annals of the New York Academy of Sciences, 2006, 1068, 458-470.	1.8	50
149	Interleukin-6 modulates production of T lymphocyteâ€"derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis and Rheumatism, 2006, 54, 158-168.	6.7	235
150	Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E456-E462.	1.8	73
151	Osteoprotegerin Overexpression by Breast Cancer Cells Enhances Orthotopic and Osseous Tumor Growth and Contrasts with That Delivered Therapeutically. Cancer Research, 2006, 66, 3620-3628.	0.4	73
152	SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. Journal of Clinical Investigation, 2006, 116, 1571-1581.	3.9	184
153	Interleukin-11 Receptor Signaling Is Required for Normal Bone Remodeling. Journal of Bone and Mineral Research, 2005, 20, 1093-1102.	3.1	138
154	Matrix Metalloproteinases Are Not Essential for Aggrecan Turnover during Normal Skeletal Growth and Development. Molecular and Cellular Biology, 2005, 25, 3388-3399.	1.1	48
155	The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line. Cancer Research, 2005, 65, 4929-4938.	0.4	133
156	Osteoclast-derived activity in the coupling of bone formation to resorption. Trends in Molecular Medicine, 2005, 11, 76-81.	3.5	550
157	The Inhibition of the Osteoblast Niche during Hematopoietic Stem Cell Mobilization Is an Indirect Effect Involving Mature Bone Marrow Leukocytes, IL6 and Soluble IL6 Receptor.. Blood, 2005, 106, 1966-1966.	0.6	1
158	gp130-Mediated Signaling Is Necessary for Normal Osteoblastic Function in Vivo and in Vitro. Endocrinology, 2004, 145, 1376-1385.	1.4	60
159	Osteopenia in Siah1a Mutant Mice. Journal of Biological Chemistry, 2004, 279, 29583-29588.	1.6	11
160	Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. Journal of Cell Biology, 2004, 167, 925-934.	2.3	198
161	Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis and Rheumatism, 2004, 50, 2338-2346.	6.7	141
162	Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. Journal of Clinical Investigation, 2004, 113, 379-389.	3.9	175

#	Article	IF	Citations
163	Generation and Analysis of Siah2 Mutant Mice. Molecular and Cellular Biology, 2003, 23, 9150-9161.	1.1	69
164	A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptorâ€“deficient mice. Journal of Clinical Investigation, 2003, 111, 1319-1327.	3.9	161
165	A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptorâ€“deficient mice. Journal of Clinical Investigation, 2003, 111, 1319-1327.	3.9	91
166	The Increased Bone Mass in Î”FosB Transgenic Mice Is Independent of Circulating Leptin Levels. Endocrinology, 2002, 143, 4304-4309.	1.4	24
167	Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. American Journal of Pathology, 2002, 161, 1419-1427.	1.9	352
168	An Ethyl-Nitrosourea-Induced Point Mutation in Phex Causes Exon Skipping, X-Linked Hypophosphatemia, and Rickets. American Journal of Pathology, 2002, 161, 1925-1933.	1.9	37
169	Regulating Î”FosB expression in adult tet-off-Î”FosB transgenic mice alters bone formation and bone mass. Bone, 2002, 30, 32-39.	1.4	23
170	Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-Î² in bone remodeling in females but not in males. Bone, 2002, 30, 18-25.	1.4	309
171	Activated parathyroid hormone/parathyroid hormoneâ€“related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. Journal of Clinical Investigation, 2001, 107, 277-286.	3.9	338
172	Overexpression of Î”FosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nature Medicine, 2000, 6, 985-990.	15.2	325
173	Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets. Diabetes, 2000, 49, 392-398.	0.3	75
174	Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation. Journal of Cell Biology, 2000, 151, 311-320.	2.3	275
175	Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB Journal, 2000, 14, 1908-1916.	0.2	155
176	Bone homeostasis in growth hormone receptorâ€“null mice is restored by IGF-I but independent of Stat5. Journal of Clinical Investigation, 2000, 106, 1095-1103.	3.9	225
177	The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in mev/mev mutant mice. Bone, 1999, 25, 261-267.	1.4	108
178	Human and Murine Osteocalcin Gene Expression: Conserved Tissue Restricted Expression and Divergent Responses to 1,25-Dihydroxyvitamin D3in Vivo. Molecular Endocrinology, 1997, 11, 1695-1708.	3.7	65
179	Estradiol treatment transiently increases trabecular bone volume in ovariectomized rats. Bone, 1996, 19, 455-461.	1.4	32
180	Increased bone resorption precedes increased bone formation in the ovariectomized rat. Calcified Tissue International, 1996, 59, 121-127.	1.5	82

#	Article	IF	Citations
181	Parathyroidectomy does not prevent bone loss in the oophorectomized rat. Journal of Bone and Mineral Research, 1994, 9, 1859-1863.	3.1	10
182	Embedded in bone, but looking beyond: osteocalcin, epigenetics and ectopic bone formation (ASBMR) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	2